Therefore, the employment of GATA3 in the determination of TME phenotypes and bladder cancer subtypes has focused on GATA3 as a promising candidate for personalized medicine for better management of bladder cancer [51]. The gene discussed is GATA3; the disease is urinary bladder carcinoma.